Sign up
Pharma Capital

ANGLE names diagnostic pathology expert Dr Joseph D Khoury as a scientific advisor

The AIM-listed liquid biopsy company pointed out that Khoury has significant experience in the cytological and morphological analysis of cancer cells
Cancer cell
It added that his expertise is therefore highly relevant to ANGLE's continuing development of its ParsortixTM system

ANGLE plc (LON:AGL) (OTCQX:ANPCY) has announced the appointment of Dr Joseph D Khoury as a scientific advisor to the company's established Scientific Advisory Board.

The AIM-listed liquid biopsy company pointed out that Khoury is a recognised expert in diagnostic pathology and has significant experience in the cytological and morphological analysis of cancer cells.

READ: ANGLE acquires remaining stake in US subsidiary from Parsortix inventor

It added that his expertise is therefore highly relevant to ANGLE's continuing development of its ParsortixTM system as the liquid biopsy platform of choice for harvesting and analysing circulating tumour cells and other rare cells from blood as a means of diagnosing and monitoring disease.

The group said Khoury is a tenured Professor of Pathology and Laboratory Medicine at The University of Texas MD Anderson Cancer Center in Houston, Texas and is the Executive Director of the MD Anderson Cancer Network for the Division of Pathology and Laboratory Medicine and the Director of the MD Anderson Institutional Immunohistochemistry Laboratory.

ANGLE founder and chief executive, Andrew Newland, commented: "Our Parsortix system has been shown to enable the efficient harvesting of circulating cancer cells and other rare cells in patient blood.

“Dr Khoury's expertise in interpreting these cells and their relevance to a patient's condition, and potentially their prognosis and treatment, is expected to open up new possibilities for the use of Parsortix system. “

View full AGL profile View Profile
View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.